MALAKOFF, France–(BUSINESS WIRE)–Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reports today the key regulatory and clinical communication achievements of the past year across congresses, publications, and expert presentations. Regulatory update: FDA submission Theraclion announces that the full dataset from the U.S. Food and Drug